Comparative Pharmacology
Head-to-head clinical analysis: MERREM IV versus PRIMAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MERREM IV versus PRIMAXIN.
MERREM IV vs PRIMAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meropenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death. Cilastatin prevents renal metabolism of imipenem by inhibiting dehydropeptidase I.
1 g intravenously every 8 hours over 15-30 minutes for complicated intra-abdominal infections; 500 mg intravenously every 8 hours for complicated skin and skin structure infections.
1 g (imipenem 500 mg + cilastatin 500 mg) IV every 6 hours for adults with normal renal function. Maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life approximately 1 hour in adults with normal renal function; prolonged to 4–6 hours in moderate renal impairment and up to 10 hours in severe impairment; clinical context: dosing interval adjustment required for CrCl <50 mL/min.
Terminal elimination half-life: 1 hour. In patients with impaired renal function, half-life extends up to 4-6 hours in moderate impairment and >10 hours in severe impairment.
Primarily renal (approximately 70% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal excretion accounts for ~20% as microbiologically inactive metabolite; minimal nonrenal clearance.
Renal (approximately 70% as unchanged drug via glomerular filtration and tubular secretion) and 20-30% biliary/fecal.
Category C
Category C
Carbapenem Antibiotic
Carbapenem Antibiotic